Aspirin hyporesponsiveness in type 2 diabetes mellitus: A systematic review with narrative synthesis of definitions, assessment methods, and clinical relevance.
Laura Ortega-Hombrados, Esther Martín-Aurioles, Ana María Sánchez-Tévar et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated aspirin hyporesponsiveness in patients with type 2 diabetes mellitus (T2DM), analyzing 21 studies. The prevalence of hyporesponsiveness varied from 0-57%, influenced by factors such as aspirin formulation and assay methods. The review found limited evidence linking hyporesponsiveness to clinical outcomes, with no major cardiovascular event reduction observed in the largest trial comparing dosing regimens.
Key findings
- Aspirin hyporesponsiveness prevalence in T2DM ranged from 0-57%, influenced by various factors.
- Twice-daily aspirin regimens may suppress platelet reactivity more effectively than once-daily dosing.
- Reduced thromboxane B2 suppression was consistently observed with enteric-coated aspirin.
- Current evidence does not support routine platelet function testing or dose escalation.
Why it matters
Understanding aspirin hyporesponsiveness in T2DM is crucial for managing cardiovascular risk, as variability in response can affect treatment efficacy. Clinicians should consider factors influencing aspirin effectiveness to optimize patient outcomes.